The results showed that the transcriptomic expression level of CCL2 is significantly positively correlated with the sensitivity to the TOP30 anti-tumor drugs, while the other five genes exhibit varying degrees of negative correlation with most drugs. Here, CCL2 is linked to neoplasm.